Anthony Jarkowski

1.7k total citations
28 papers, 715 citations indexed

About

Anthony Jarkowski is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Anthony Jarkowski has authored 28 papers receiving a total of 715 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Oncology, 9 papers in Pulmonary and Respiratory Medicine and 5 papers in Molecular Biology. Recurrent topics in Anthony Jarkowski's work include Cancer Immunotherapy and Biomarkers (11 papers), Renal cell carcinoma treatment (4 papers) and CAR-T cell therapy research (4 papers). Anthony Jarkowski is often cited by papers focused on Cancer Immunotherapy and Biomarkers (11 papers), Renal cell carcinoma treatment (4 papers) and CAR-T cell therapy research (4 papers). Anthony Jarkowski collaborates with scholars based in United States, France and United Kingdom. Anthony Jarkowski's co-authors include Alan Forrest, Dana R. Anderson, Brian T. Tsuji, Lauren Lim, Jenny C. Yang, Jürgen B. Bulitta, Neang S. Ly, Nikhil I. Khushalani, Michael K. Wong and Joseph J. Skitzki and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and International Journal of Radiation Oncology*Biology*Physics.

In The Last Decade

Anthony Jarkowski

28 papers receiving 700 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Anthony Jarkowski United States	13	256	256	181	143	131	28	715
Jānis Gardovskis Latvia	16	235 0.9×	255 1.0×	140 0.8×	210 1.5×	215 1.6×	93	1.1k
Luning Zhuang United States	17	107 0.4×	239 0.9×	144 0.8×	278 1.9×	186 1.4×	24	643
Naoki Matsumura Japan	15	196 0.8×	174 0.7×	93 0.5×	66 0.5×	154 1.2×	42	690
A. Benouda Morocco	11	70 0.3×	286 1.1×	146 0.8×	52 0.4×	137 1.0×	18	753
Vasiliki Rapti Greece	9	65 0.3×	203 0.8×	109 0.6×	104 0.7×	123 0.9×	29	771
Irfan Ali Mirza Pakistan	11	128 0.5×	256 1.0×	202 1.1×	55 0.4×	83 0.6×	53	649
Yueling Wang China	16	122 0.5×	131 0.5×	188 1.0×	49 0.3×	316 2.4×	52	927
Koichi Kitagawa Japan	18	160 0.6×	122 0.5×	242 1.3×	60 0.4×	248 1.9×	68	916
Patricia Palacios Switzerland	18	319 1.2×	136 0.5×	135 0.7×	20 0.1×	155 1.2×	41	1.1k
Suzanne P. M. Lutgens Netherlands	11	70 0.3×	97 0.4×	128 0.7×	46 0.3×	182 1.4×	16	697

Countries citing papers authored by Anthony Jarkowski

Since Specialization

Citations

This map shows the geographic impact of Anthony Jarkowski's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anthony Jarkowski with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anthony Jarkowski more than expected).

Fields of papers citing papers by Anthony Jarkowski

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anthony Jarkowski. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anthony Jarkowski. The network helps show where Anthony Jarkowski may publish in the future.

Co-authorship network of co-authors of Anthony Jarkowski

This figure shows the co-authorship network connecting the top 25 collaborators of Anthony Jarkowski. A scholar is included among the top collaborators of Anthony Jarkowski based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anthony Jarkowski. Anthony Jarkowski is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Khushalani, Nikhil I., Adi Diab, Paolo A. Ascierto, et al.. (2020). Bempegaldesleukin plus nivolumab in untreated, unresectable or metastatic melanoma: Phase III PIVOT IO 001 study design. Future Oncology. 16(28). 2165–2175. 17 indexed citations

Khushalani, Nikhil I., Adi Diab, Paolo A. Ascierto, et al.. (2019). CA045-001: A phase III, randomized, open label study of bempegaldesleukin (NKTR-214) plus nivolumab (NIVO) versus NIVO monotherapy in patients (pts) with previously untreated, unresectable or metastatic melanoma (MEL).. Journal of Clinical Oncology. 37(15_suppl). TPS9601–TPS9601. 4 indexed citations

Siu, Lillian L., Caroline Even, Ricard Mesı́a, et al.. (2018). A Randomized, Open-Label, Multicenter, Global Phase 2 Study of Durvalumab (D), Tremelimumab (T), or D Plus T, in Patients With PD-L1 Low/Negative Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: CONDOR. International Journal of Radiation Oncology*Biology*Physics. 100(5). 1307–1307. 7 indexed citations

Zandberg, Dan P., Alain P. Algazi, Antonio Jimeno, et al.. (2017). Durvalumab for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Preliminary results from a single-arm, phase 2 study. Annals of Oncology. 28. v372–v372. 24 indexed citations

Licitra, Lisa, Caroline Even, Robert I. Haddad, et al.. (2015). 341TiP Phase 3 study of durvalumab (MEDI4736) alone or in combination with tremelimumab versus standard of care (SoC) in platinum-resistant recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): EAGLE. Annals of Oncology. 26. ix93–ix93. 1 indexed citations

Rizvi, Naiyer A., Fabrice Barlési, Julie R. Brahmer, et al.. (2015). Phase III, randomized, open-label study of durvalumab (MEDI4736) in combination with tremelimumab or durvalumab alone versus platinum-based chemotherapy in first-line treatment of patients with advanced/metastatic NSCLC: MYSTIC. Journal for ImmunoTherapy of Cancer. 3(S2). 6 indexed citations

Ferris, Robert L., Makoto Tahara, Trishna Goswami, et al.. (2015). Phase III, randomized, open-label study of durvalumab (MEDI4736) monotherapy, or durvalumab + tremelimumab, versus standard of care (SoC), in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): eagle. Journal for ImmunoTherapy of Cancer. 3(S2). 19 indexed citations

Gilbert, Jill, Christophe Le Tourneau, Hisham Mehanna, et al.. (2015). Phase II, randomized, open-label study of durvalumab (MEDI4736) or tremelimumab monotherapy, or durvalumab + tremelimumab, in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): CONDOR. Journal for ImmunoTherapy of Cancer. 3(S2). 9 indexed citations

Khushalani, Nikhil I. & Anthony Jarkowski. (2014). BRAF and beyond: Tailoring strategies for the individual melanoma patient. Journal of Carcinogenesis. 13(1). 1–1. 17 indexed citations

10.

Lam, Elaine T., Michael K. Wong, Neeraj Agarwal, et al.. (2014). Retrospective Analysis of the Safety and Efficacy of High-dose Interleukin-2 After Prior Tyrosine Kinase Inhibitor Therapy in Patients With Advanced Renal Cell Carcinoma. Journal of Immunotherapy. 37(7). 360–365. 9 indexed citations

11.

Jarkowski, Anthony, Peter Loud, Joseph J. Skitzki, et al.. (2014). Systemic Therapy in Advanced Cutaneous Squamous Cell Carcinoma (CSCC). American Journal of Clinical Oncology. 39(6). 545–548. 84 indexed citations

12.

Jarkowski, Anthony, LeAnn B. Norris, & Van Anh Trinh. (2014). Controversies in the Management of Advanced Melanoma. Annals of Pharmacotherapy. 48(11). 1456–1468. 10 indexed citations

13.

Khushalani, Nikhil I., et al.. (2014). Immunotherapy in Melanoma. Journal of Pharmacy Practice. 28(2). 193–203. 8 indexed citations

14.

Jarkowski, Anthony, et al.. (2013). Dose rounding of ipilimumab in adult metastatic melanoma patients results in significant cost savings. Journal of Oncology Pharmacy Practice. 20(1). 47–50. 19 indexed citations

15.

Lam, Elaine T., Nitin Agarwal, Bruce G. Redman, et al.. (2011). Safety and efficacy of sequencing high-dose interleukin 2 (IL2) after tyrosine kinase inhibitor (TKI) therapy for metastatic renal cell carcinoma.. Journal of Clinical Oncology. 29(15_suppl). e15079–e15079. 1 indexed citations

16.

Jarkowski, Anthony, et al.. (2010). Heart Failure Caused by Molecularly Targeted Therapies for Cancer. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 31(1). 62–75. 2 indexed citations

17.

Lim, Lauren, Neang S. Ly, Dana R. Anderson, et al.. (2010). Resurgence of Colistin: A Review of Resistance, Toxicity, Pharmacodynamics, and Dosing. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 30(12). 1279–1291. 339 indexed citations

18.

Glode, Ashley E. & Anthony Jarkowski. (2009). Bendamustine: A New Treatment Option for Chronic Lymphocytic Leukemia. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 29(11). 1375–1384. 7 indexed citations

19.

Wong, Michael K. & Anthony Jarkowski. (2009). Response to Sorafenib After Sunitinib‐Induced Acute Heart Failure in a Patient with Metastatic Renal Cell Carcinoma: Case Report and Review of the Literature. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 29(4). 473–478. 22 indexed citations

20.

Jarkowski, Anthony, et al.. (2008). Nilotinib: A New Tyrosine Kinase Inhibitor for the Treatment of Chronic Myelogenous Leukemia. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 28(11). 1374–1382. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact